Treatment and Day-to-Day Management
At a Glance
Apparent mineralocorticoid excess is managed with medicines that block cortisol’s salt-retaining effect, potassium and kidney-function monitoring, a low-sodium diet, and specialist follow-up; dexamethasone or transplant may be considered in selected cases.
Managing Apparent Mineralocorticoid Excess (AME) is a balancing act. The goal of treatment is not just to lower blood pressure, but to restore the chemical harmony that the missing enzyme usually provides. By blocking the “fake” signals from cortisol and protecting the kidneys from salt overload, you or your child can achieve stable health and normal growth [1][2].
The Standard of Care: The “Block and Replace” Strategy
Because AME is rare, there is no single evidence-based sequence for all patients, and treatments are chosen and combined according to severity and kidney function [3]. The first line of defense typically involves:
- Mineralocorticoid Receptor Antagonists (MRAs): Medications like spironolactone or eplerenone act as “plugs” for the receptors in the kidney. They stop cortisol from turning on the salt-saving switch [3][4].
- Potassium Supplementation: Because the kidneys “leak” potassium in AME, daily oral potassium supplements (often potassium chloride) are usually prescribed to prevent muscle weakness and heart rhythm issues [3][7].
- ENaC Blockers: Doctors may also add amiloride, which blocks the specific sodium channels that are stuck in the “open” position [8][9].
Critical Safety Warning: Spironolactone, eplerenone, amiloride, and potassium supplements can all increase potassium levels. Combining them carries a severe risk of hyperkalemia (dangerously high potassium), especially when kidney function fluctuates. The guide should explicitly require laboratory monitoring and prohibit unsupervised dose changes.
Second-Line Treatment: The Cortisol-Cutting Approach
In selected patients, a specialist may introduce low-dose dexamethasone [10][4].
It may seem strange to give a steroid (dexamethasone) to treat a condition caused by a steroid (cortisol). However, dexamethasone works by telling the brain’s “control center” (the pituitary gland) to stop producing ACTH. Without ACTH, the body makes much less of its own natural cortisol [11]. With less cortisol circulating, there is less “fuel” to trigger the salt-saving receptors in the kidney [4][11].
Dexamethasone Safety:
- Adrenal Suppression: Dexamethasone suppresses the body’s natural stress response. Never stop it abruptly, as this can cause a life-threatening adrenal crisis.
- Families must receive instructions about “stress dosing” during illness, fever, or surgery.
- It carries risks of Cushingoid features, infection risk, glucose changes, and can itself impair pediatric growth; it requires careful monitoring.
Dietary Management: The Salt Factor
Because AME makes the body hypersensitive to salt, a low-sodium diet is a cornerstone of daily life [12][8].
- Why it works: In AME, salt is more likely to be “trapped” in the blood, pulling in water and raising blood pressure [8].
- Practical Steps: A pediatric dietitian can provide a dietitian-directed, age-appropriate approach that preserves calories and growth [7][2].
- Warning: Check all supplements and salt substitutes with the care team, as many salt substitutes replace sodium with potassium, which can be fatal when taking MRAs or amiloride.
Treatment Progression
| Phase | Treatment Focus | Primary Goal |
|---|---|---|
| First Line Options | Spironolactone/Eplerenone + Potassium | Block cortisol’s access to the kidney and stabilize electrolytes [3]. |
| Additional Therapies | Add Amiloride or Low-Dose Dexamethasone | Further reduce salt reabsorption or lower the body’s cortisol production [8][10]. |
| Advanced Management | Multi-drug Hypertensive Therapy | Control resistant high blood pressure to protect the heart and brain [7]. |
The Role of Kidney Transplantation
For some patients, despite medical management, the kidneys may develop scarring leading to advanced chronic kidney disease (CKD) [5].
In severe kidney failure under standard transplant indications, a kidney transplant may be considered. Correction of the AME renal phenotype has been reported because the donor kidney has functional 11β-HSD2 enzymes, but it is a rare case-based possibility, not a predictable cure [4]. Post-transplant blood-pressure treatment and specialist monitoring may still be needed.
Common questions in this guide
What medicines are commonly used to treat apparent mineralocorticoid excess?
Why are blood tests important when treating AME?
Why might dexamethasone be prescribed for AME?
What type of diet can help control apparent mineralocorticoid excess?
Can apparent mineralocorticoid excess lead to kidney failure or a transplant?
How can families manage AME safely at home?
Get notified when new evidence is published on Apparent mineralocorticoid excess.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Apparent mineralocorticoid excess.
Funder JW
The Journal of steroid biochemistry and molecular biology 2017; (165(Pt A)):151-153 doi:10.1016/j.jsbmb.2016.03.010.
PMID: 26956190 - 2
Apparent mineralocorticoid excess with a novel HSD11B2 variant: longitudinal clinical and biochemical follow-Up.
Nalluri BT, Kudugunti N, Sahay RK
JCEM case reports 2026; (4(6)):luag083 doi:10.1210/jcemcr/luag083.
PMID: 42064719 - 3
Case report: Clinical characteristics and Genetical analysis of HSD11B2 in three Chinese children with apparent mineralocorticoid excess: a case series.
Ding Y, Cheng M, Cao B, et al.
Frontiers in endocrinology 2024; (15()):1491825 doi:10.3389/fendo.2024.1491825.
PMID: 39931437 - 4
Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.
Razzaghy-Azar M, Yau M, Khattab A, New MI
The Journal of steroid biochemistry and molecular biology 2017; (165(Pt A)):145-150 doi:10.1016/j.jsbmb.2016.02.014.
PMID: 26892095 - 5
Apparent mineralocorticoid excess in Israel: a case series and literature review.
Lebel A, Ben Shalom E, Mokatern R, et al.
European journal of endocrinology 2024; (190(5)):347-353 doi:10.1093/ejendo/lvae049.
PMID: 38652803 - 6
Mineralocorticoid hypertension and hypokalaemia induced by posaconazole.
Boughton C, Taylor D, Ghataore L, et al.
Endocrinology, diabetes & metabolism case reports 2018; (2018()) doi:10.1530/EDM-17-0157.
PMID: 29472988 - 7
Apparent mineralocorticoid excess mimicking Bartter syndrome in infancy.
Hatipoğlu S, Yıldırım E, Şalbaş ÖY, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2026; doi:10.1515/jpem-2026-0333.
PMID: 42912472 - 8
Renal Dysfunction Induced by Kidney-Specific Gene Deletion of Hsd11b2 as a Primary Cause of Salt-Dependent Hypertension.
Ueda K, Nishimoto M, Hirohama D, et al.
Hypertension (Dallas, Tex. : 1979) 2017; (70(1)):111-118 doi:10.1161/HYPERTENSIONAHA.116.08966.
PMID: 28559392 - 9
Diagnosing apparent mineralocorticoid excess in a child with hypertension and nephrocalcinosis: from symptoms to genetics.
Vallabhaneni P, Hasan SKS, Tiewsoh K, et al.
CEN case reports 2025; (14(5)):786-792 doi:10.1007/s13730-025-01015-z.
PMID: 40720003 - 10
Apparent Mineralocorticoid Excess Syndrome: Case Report.
Alsaadoun SA, Alrasheedi AT, Gazar SH, Alsallum GA
International medical case reports journal 2025; (18()):671-676 doi:10.2147/IMCRJ.S520238.
PMID: 40487050 - 11
Conditional Deletion of Hsd11b2 in the Brain Causes Salt Appetite and Hypertension.
Evans LC, Ivy JR, Wyrwoll C, et al.
Circulation 2016; (133(14)):1360-70 doi:10.1161/CIRCULATIONAHA.115.019341.
PMID: 26951843 - 12
Classic and Nonclassic Apparent Mineralocorticoid Excess Syndrome.
Carvajal CA, Tapia-Castillo A, Vecchiola A, et al.
The Journal of clinical endocrinology and metabolism 2020; (105(4)) doi:10.1210/clinem/dgz315.
PMID: 31909799
This page is for informational purposes only and does not constitute medical advice. Do not change or stop AME medicines without guidance from your child's care team.